Stocks · News reference

SciSparc shares are trading higher after the company announced its subsidiary, NeuroThera labs, continued advancement in participant enrollment for the clinical trial assessing the SCI-210 treatment for symptoms associated with autism spectrum disorder

Aug 31, 2026, 8:04 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 2, 2026, 12:18 PMBenzinga Newsdesk
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment
SPRC
BenzingaAug 31, 2026, 8:04 PMBenzinga Newsdesk
SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel
SPRC TSXV:NTLX
BenzingaAug 26, 2026, 12:37 PMBenzinga Newsdesk
SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1
The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI marketTEL AVIV, Israel, Aug. 26, 2026 (GLOBE
SPRC